Blood Pressure and Glucose Control in Patients With Diabetes

Giuseppe Mancia

Research output: Contribution to journalArticle

Abstract

Type 2 diabetes mellitus and hypertension are comorbid clinical conditions that synergize to create a vascular environment that significantly increases the risk of macrovascular disease (eg, myocardial infarction, stroke, and cardiovascular mortality) and microvascular disease (eg, nephropathy and retinopathy). Given the prevalence of this comorbid association, the large majority of patients with newly diagnosed Type 2 diabetes are hypertensive. The co-management of diabetes, through glucose control (targeting a hemoglobin A1c 1c and BP, treatment strategies that combine multiple hypertensive agents and glucose-controlling agents are being investigated. Treatments that include an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker may be of particular value, because these drug classes inhibit the renin-angiotensin system, which mediates the increase in renovascular resistance and intraglomerular pressure observed in diabetic kidneys. Inhibition of the renin-angiotensin system, which protects the kidney through a variety of mechanisms, may also provide renal and cardiovascular benefits that extend beyond those attributable to BP control. Thus, the effective co-management of diabetes and hypertension through combined glucose and BP control remains an unmet medical need for which strategies still need to be developed.

Original languageEnglish
JournalAmerican Journal of Hypertension
Volume20
Issue number7 SUPPL.
DOIs
Publication statusPublished - Jul 2007

Fingerprint

Blood Glucose
Renin-Angiotensin System
Blood Pressure
Kidney
Glucose
Type 2 Diabetes Mellitus
Myocardial Infarction
Hypertension
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Blood Vessels
Hemoglobins
Pressure
Mortality
Therapeutics
Pharmaceutical Preparations

Keywords

  • angiotensin-converting enzyme inhibitors
  • Diabetes mellitus
  • hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Blood Pressure and Glucose Control in Patients With Diabetes. / Mancia, Giuseppe.

In: American Journal of Hypertension, Vol. 20, No. 7 SUPPL., 07.2007.

Research output: Contribution to journalArticle

@article{6202e21c8f214dcc96e20c5f00fd81fc,
title = "Blood Pressure and Glucose Control in Patients With Diabetes",
abstract = "Type 2 diabetes mellitus and hypertension are comorbid clinical conditions that synergize to create a vascular environment that significantly increases the risk of macrovascular disease (eg, myocardial infarction, stroke, and cardiovascular mortality) and microvascular disease (eg, nephropathy and retinopathy). Given the prevalence of this comorbid association, the large majority of patients with newly diagnosed Type 2 diabetes are hypertensive. The co-management of diabetes, through glucose control (targeting a hemoglobin A1c 1c and BP, treatment strategies that combine multiple hypertensive agents and glucose-controlling agents are being investigated. Treatments that include an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker may be of particular value, because these drug classes inhibit the renin-angiotensin system, which mediates the increase in renovascular resistance and intraglomerular pressure observed in diabetic kidneys. Inhibition of the renin-angiotensin system, which protects the kidney through a variety of mechanisms, may also provide renal and cardiovascular benefits that extend beyond those attributable to BP control. Thus, the effective co-management of diabetes and hypertension through combined glucose and BP control remains an unmet medical need for which strategies still need to be developed.",
keywords = "angiotensin-converting enzyme inhibitors, Diabetes mellitus, hypertension",
author = "Giuseppe Mancia",
year = "2007",
month = "7",
doi = "10.1016/j.amjhyper.2007.04.016",
language = "English",
volume = "20",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "7 SUPPL.",

}

TY - JOUR

T1 - Blood Pressure and Glucose Control in Patients With Diabetes

AU - Mancia, Giuseppe

PY - 2007/7

Y1 - 2007/7

N2 - Type 2 diabetes mellitus and hypertension are comorbid clinical conditions that synergize to create a vascular environment that significantly increases the risk of macrovascular disease (eg, myocardial infarction, stroke, and cardiovascular mortality) and microvascular disease (eg, nephropathy and retinopathy). Given the prevalence of this comorbid association, the large majority of patients with newly diagnosed Type 2 diabetes are hypertensive. The co-management of diabetes, through glucose control (targeting a hemoglobin A1c 1c and BP, treatment strategies that combine multiple hypertensive agents and glucose-controlling agents are being investigated. Treatments that include an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker may be of particular value, because these drug classes inhibit the renin-angiotensin system, which mediates the increase in renovascular resistance and intraglomerular pressure observed in diabetic kidneys. Inhibition of the renin-angiotensin system, which protects the kidney through a variety of mechanisms, may also provide renal and cardiovascular benefits that extend beyond those attributable to BP control. Thus, the effective co-management of diabetes and hypertension through combined glucose and BP control remains an unmet medical need for which strategies still need to be developed.

AB - Type 2 diabetes mellitus and hypertension are comorbid clinical conditions that synergize to create a vascular environment that significantly increases the risk of macrovascular disease (eg, myocardial infarction, stroke, and cardiovascular mortality) and microvascular disease (eg, nephropathy and retinopathy). Given the prevalence of this comorbid association, the large majority of patients with newly diagnosed Type 2 diabetes are hypertensive. The co-management of diabetes, through glucose control (targeting a hemoglobin A1c 1c and BP, treatment strategies that combine multiple hypertensive agents and glucose-controlling agents are being investigated. Treatments that include an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker may be of particular value, because these drug classes inhibit the renin-angiotensin system, which mediates the increase in renovascular resistance and intraglomerular pressure observed in diabetic kidneys. Inhibition of the renin-angiotensin system, which protects the kidney through a variety of mechanisms, may also provide renal and cardiovascular benefits that extend beyond those attributable to BP control. Thus, the effective co-management of diabetes and hypertension through combined glucose and BP control remains an unmet medical need for which strategies still need to be developed.

KW - angiotensin-converting enzyme inhibitors

KW - Diabetes mellitus

KW - hypertension

UR - http://www.scopus.com/inward/record.url?scp=34249300835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249300835&partnerID=8YFLogxK

U2 - 10.1016/j.amjhyper.2007.04.016

DO - 10.1016/j.amjhyper.2007.04.016

M3 - Article

AN - SCOPUS:34249300835

VL - 20

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 7 SUPPL.

ER -